Literature DB >> 24048630

Antiarrhythmic drugs 2013: state of the art.

Kapil Kumar1, Peter J Zimetbaum.   

Abstract

Antiarrhythmic drugs are widely used, but are of modest efficacy and have important side effects. However, even with the advance of catheter ablation for atrial fibrillation and ventricular tachycardia, antiarrhythmic drugs remain an important tool for treating arrhythmias. Antiarrhythmic drug development has remained slow despite much effort given our limited understanding of what role various ionic currents play in arrhythmogenesis and how they are modified by arrhythmias. This review will focus on promising new antiarrhythmic drugs undergoing clinical investigation or currently approved for clinical use, including amiodarone analogues, agents with novel ionic targets, and new drug combinations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048630     DOI: 10.1007/s11886-013-0410-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  56 in total

1.  A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.

Authors:  Jean-Yves Le Heuzey; Gaetano M De Ferrari; David Radzik; Massimo Santini; Junren Zhu; Jean-Marc Davy
Journal:  J Cardiovasc Electrophysiol       Date:  2010-04-06

2.  Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.

Authors:  Federico Lombardi; Martin Borggrefe; Witold Ruzyllo; Berndt Lüderitz
Journal:  Eur Heart J       Date:  2006-08-25       Impact factor: 29.983

3.  Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine.

Authors:  Shomu Bohora; Yash Lokhandwala; Pritesh Parekh; Apurva Vasavda
Journal:  J Cardiovasc Electrophysiol       Date:  2011-03

4.  Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Authors:  Peter R Kowey; Harry J G M Crijns; Etienne M Aliot; Alessandro Capucci; Piotr Kulakowski; David Radzik; Denis Roy; Stuart J Connolly; Stefan H Hohnloser
Journal:  Circulation       Date:  2011-11-14       Impact factor: 29.690

5.  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Authors:  Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2010-10-05       Impact factor: 24.094

6.  Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Authors:  Paul Dorian; Martin Borggrefe; Hussein R Al-Khalidi; Stefan H Hohnloser; Jose M Brum; Daljit S Tatla; Johannes Brachmann; Robert J Myerburg; David S Cannom; Michael van der Laan; Michael J Holroyde; Igor Singer; Craig M Pratt
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

7.  Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.

Authors:  T Jared Bunch; Srijoy Mahapatra; David Murdock; Jamie Molden; J Peter Weiss; Heidi T May; Tami L Bair; Katy M Mader; Brian G Crandall; John D Day; Jeffrey S Osborn; Joseph B Muhlestein; Donald L Lappe; Jeffrey L Anderson
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-03       Impact factor: 1.976

8.  Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.

Authors:  Avinash R Khitri; Etienne M Aliot; Alessandro Capucci; Stuart J Connolly; Harry Crijns; Stefan H Hohnloser; Piotr Kulakowski; Denis Roy; David Radzik; Peter R Kowey
Journal:  J Cardiovasc Electrophysiol       Date:  2011-12-15

9.  Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.

Authors:  Arthur Beyder; Peter R Strege; Santiago Reyes; Cheryl E Bernard; Andre Terzic; Jonathan Makielski; Michael J Ackerman; Gianrico Farrugia
Journal:  Circulation       Date:  2012-05-07       Impact factor: 29.690

10.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  6 in total

Review 1.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

2.  Arrhythmogenic effects of mutated L-type Ca 2+-channels on an optogenetically paced muscular pump in Caenorhabditis elegans.

Authors:  Christina Schüler; Elisabeth Fischer; Lior Shaltiel; Wagner Steuer Costa; Alexander Gottschalk
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

3.  Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence.

Authors:  Megan A Cummins; Pavan J Dalal; Marco Bugana; Stefano Severi; Eric A Sobie
Journal:  PLoS Comput Biol       Date:  2014-03-27       Impact factor: 4.475

4.  Trigger vs. Substrate: Multi-Dimensional Modulation of QT-Prolongation Associated Arrhythmic Dynamics by a hERG Channel Activator.

Authors:  Michael A Colman; Erick A Perez Alday; Arun V Holden; Alan P Benson
Journal:  Front Physiol       Date:  2017-10-04       Impact factor: 4.566

5.  Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.

Authors:  Sayoko Kinoshita; Kouichi Hosomi; Satoshi Yokoyama; Mitsutaka Takada
Journal:  Int J Med Sci       Date:  2020-01-16       Impact factor: 3.738

6.  Therapeutic monitoring of amiodarone and desethylamiodarone after surgical ablation of atrial fibrillation-evaluation of the relationship between clinical effect and the serum concentration.

Authors:  Erika Hrudikova; Milan Grundmann; Martin Kolek; Romana Urinovska; Ivana Kacirova
Journal:  Saudi Pharm J       Date:  2021-03-31       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.